{sup 188}Rhenium-HEDP in the Treatment of Pain in Bone Metastases
Systemic use of radiopharmaceuticals is a recognized alternative method for the treatment of pain in patients with multiple bone metastasis. A new option, {sup 188}Re-HEDP is proposed, using generator-obtained {sup 188}Rhenium ({beta} energy = 2.1 MeV, {gamma} energy = 155 keV, half-life = 16.9 hours). After establishing parameters of biodistribution, dosimetry and image acquisition in mice, rats and rabbits, Phase I and II studies were conducted on 12 patients with multiple metastasis from carcinomas, with pain surpassing other analgesic options. More than 50% pain relief was found in 91% of the patients, with total relief during a variable period in 41% of them allowing opiate and other analgesic drugs to be decreased or withdrawn, and showing a lower bone marrow contribution to total absorbed dose than that reported for other similar radiopharmaceuticals. Further study of this option is recommended in order to determine higher dose protocols without toxic bone marrow reaction possibilities.
- Research Organization:
- Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
- Sponsoring Organization:
- USDOE Office of Energy Research (ER) (US)
- DOE Contract Number:
- AC05-96OR22464
- OSTI ID:
- 6243
- Report Number(s):
- ORNL/CP-102530; KP 14 01 02 0; KP 14 01 02 0; TRN: US0101724
- Resource Relation:
- Conference: International Seminar on Therapeutic Applications of Radiopharmaceuticals, Hyderabad (IN), 01/18/1999--01/22/1999; Other Information: PBD: 18 Jan 1999
- Country of Publication:
- United States
- Language:
- English
Similar Records
Palliation and Survival After Repeated Re-188-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospsective Analysis
Bone marrow adsorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts